10-Q: Sight Sciences Reports Q3 Loss Narrows Amid Restructuring

Sight Sciences, Inc. reported a narrower net loss in Q3 2025, driven by significant operating expense reductions and workforce restructuring, despite an overall revenue decline.

Summary

• Net loss for the three months ended September 30, 2025, improved to $8.2 million from $11.1 million in the prior year, a 26.2% improvement.
• Total revenue for Q3 2025 decreased by 1.2% to $19.9 million, compared to $20.2 million in Q3 2024.
• Surgical Glaucoma revenue increased by 5.8% to $19.7 million in Q3 2025, primarily due to increased unit sales and average selling prices.
• Dry Eye revenue significantly decreased by 87.7% to $0.2 million in Q3 2025, mainly due to lower demand following a price increase and a strategic shift towards reimbursed market access.
• Operating expenses decreased by 10.8% to $25.1 million in Q3 2025, largely due to a strategic reduction in force and other cost-cutting measures.
• For the nine months ended September 30, 2025, total revenue decreased by 6.3% to $57.0 million, and net loss improved by 13.6% to $34.3 million.
• Cash and cash equivalents stood at $92.4 million as of September 30, 2025, down from $120.4 million at December 31, 2024.
• The company implemented a targeted restructuring plan in August 2025, reducing its global workforce by approximately 20%, incurring $2.8 million in related expenses in Q3 2025.
• Two Medicare Administrative Contractors (MACs) established jurisdiction-wide pricing for TearCare procedures (CPT code 0563T), effective retroactively to January 1, 2025, announced on October 17, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the company successfully narrowed its net loss and improved operating loss through aggressive cost-cutting and workforce reduction, the underlying revenue decline, particularly in the Dry Eye segment, and increased cash burn from operations are significant concerns. Positive reimbursement news for TearCare offers future potential, but current financial performance remains challenging, compounded by ongoing legal risks and tariff impacts.

Positives

• Net loss significantly narrowed by 26.2% in Q3 2025 and 13.6% for the nine months ended September 30, 2025, demonstrating improved financial efficiency.
• Loss from operations improved by 29.6% in Q3 2025 and 13.4% for the nine months ended September 30, 2025, indicating better control over core business expenses.
• Total gross profit increased by 1.7% in Q3 2025, and overall gross margin improved to 86.4% from 83.9% in the prior year comparable period.
• Surgical Glaucoma segment revenue grew by 5.8% in Q3 2025, driven by increased unit sales and average selling prices.
• Dry Eye segment gross margin improved to 52.1% for the nine months ended September 30, 2025, from 45.8% in the prior year, despite lower revenue, due to higher average selling prices.
• The company successfully secured jurisdiction-wide pricing from two MACs for TearCare procedures (CPT code 0563T), effective retroactively to January 1, 2025, which is expected to boost demand.
• The interest-only period for the Hercules Loan Agreement was extended by six months to February 1, 2027, providing additional financial flexibility.
• Operating expenses decreased significantly due to a strategic reduction in force and other cost-cutting measures, aligning the operating structure for long-term profitability.

Negatives

• Total revenue decreased by 1.2% in Q3 2025 and 6.3% for the nine months ended September 30, 2025, indicating overall sales challenges.
• Dry Eye segment revenue plummeted by 87.7% in Q3 2025 and 75.0% for the nine months ended September 30, 2025, primarily due to reduced demand after a price increase.
• Surgical Glaucoma revenue for the nine months ended September 30, 2025, decreased by 1.9%, impacted by reimbursement coverage changes and increased competition.
• Cash used in operating activities increased to $27.9 million for the nine months ended September 30, 2025, from $18.9 million in the prior year, indicating higher cash burn.
• Accumulated deficit increased to $380.6 million as of September 30, 2025, from $346.3 million at December 31, 2024, reflecting continued losses.
• U.S. tariffs on products imported from China increased cost of goods sold by $0.6 million for the Surgical Glaucoma segment in the nine months ended September 30, 2025, and are expected to continue impacting gross margins.
• Dry Eye gross margin decreased to 37.8% in Q3 2025 from 47.7% in the prior year, primarily due to higher overhead costs per unit associated with lower sales volumes.
• Investment income decreased by $0.5 million in Q3 2025 and $1.5 million for the nine months ended September 30, 2025, due to lower investment balances and yields.

Risks

• Ability to obtain and maintain sufficient reimbursement for products, especially protecting Surgical Glaucoma reimbursement and expanding Dry Eye reimbursement beyond the two MACs.
• Uncertainty regarding the timing and amount of reimbursement decisions from other Medicare Administrative Contractors and commercial payors for TearCare procedures.
• Potential for other third-party payors to assign insufficient payment values for TearCare procedures, hindering commercial growth and adoption.
• Adverse impact on the April 2024 jury verdict of $34 million in the patent infringement lawsuit against Alcon if ex parte reexamination proceedings result in final, non-appealable judgments of invalidity of the asserted patents.
• Continued adverse revenue impacts from restrictions on multiple MIGS procedures in combination with cataract surgery for Medicare patients in certain jurisdictions.
• Adverse impact on gross margins from U.S. tariffs on products and components imported from China, with unmitigated tariff exposure for Surgical Glaucoma estimated at $1.0 million to $1.5 million for full year 2025.
• Reliance on a limited number of third-party manufacturers, many of which are single-source suppliers, for components and assembly, particularly from China, posing supply chain risks.
• Geopolitical tensions and trade policies between the U.S. and China, which could lead to further tariffs or supply chain disruptions.
• Need for additional capital through equity or debt financing to fund operations and planned growth, as the company expects to incur additional losses for at least the next several years.
• Volatility of the trading price of common stock.

Future Outlook

The company expects to incur additional losses for at least the next several years and may seek additional debt and/or equity financing. Demand for TearCare products is anticipated to increase starting in Q4 2025 due to established MAC pricing. The company is actively expanding third-party manufacturing capacity outside of China, with new options expected to be available starting in Q1 2026 for certain products, to mitigate tariff impacts. They will continue to invest in product development, market access, sales and marketing, clinical studies, and education initiatives.

Management Comments

• Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing.
• We are focused on educating surgeons on the clinical benefits of earlier interventions with the comprehensive OMNI procedure, engagement efforts with accounts in light of reimbursement clarity, enhanced competitive counter selling, investments in targeted commercial resources, pseudophakic standalone market development, and the recent launch of our OMNI Edge Surgical System.
• We plan to continue to engage with other MACs, third-party payors, the clinical societies, and other stakeholders in continued support of patient access for interventional meibomian gland disease procedures performed with the TearCare System.
• With the pricing established by Novitas and FCSO, we believe demand for TearCare will increase beginning in the fourth quarter of 2025.
• We have dedicated meaningful resources to execute our commercial strategy, while also seeking to reduce operating expenses and improve cost efficiencies to better align our operating structure for long-term, profitable growth.

Industry Context

The ophthalmic medical device industry is highly competitive and rapidly changing. Sight Sciences operates in the glaucoma and dry eye disease segments, both of which are prevalent and underserved. The company's focus on interventional technologies and direct sales model aims to differentiate it. Reimbursement policies, particularly from Medicare Administrative Contractors (MACs) and commercial insurers, significantly influence product adoption and market access. The recent MAC pricing for TearCare is a positive step for the dry eye segment, which has historically relied on cash-pay models. However, the glaucoma segment faces challenges from evolving reimbursement rules and increased competition from other minimally invasive glaucoma surgery (MIGS) devices.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a patent infringement lawsuit against Ivantis, Inc. and Alcon Inc. regarding the Hydrus Microstent, alleging infringement of U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, 10,314,742, and 11,389,328.
• On April 26, 2024, a jury awarded the company $34 million ($5.5 million in lost profits and $28.5 million in royalty damages) for commercial sales of the Hydrus Microstent.
• In March 2025, after unsuccessful mediation, the company and Alcon requested the Court to rule on post-trial motions and enter a judgment, which has not yet occurred.
• In June 2025, Alcon filed petitions with the USPTO for ex parte reexaminations challenging the validity of the three patents asserted at trial, which the USPTO granted.
• The outcome of the ex parte reexamination proceedings could materially and adversely impact the jury verdict, including potentially vacating the verdict or finding the patents invalid.

Stakeholder Impact

• **Shareholders**: The narrowing net loss and cost-cutting measures could be viewed positively, but declining revenue and increased cash burn, coupled with ongoing legal and reimbursement uncertainties, may create volatility in share price. The potential for future equity financing could dilute existing shareholders.
• **Employees**: The strategic reduction in force (approximately 20% of global workforce) in August 2025 directly impacts employees through layoffs, though it aims to improve long-term profitability for the remaining workforce.
• **Customers (ECPs)**: The price increase for TearCare products negatively impacted demand, but the recent MAC pricing decisions are expected to increase demand and patient access, potentially benefiting ECPs who adopt the system. Reimbursement changes for Surgical Glaucoma products continue to affect ECPs' utilization.
• **Suppliers**: Reliance on a limited number of third-party manufacturers, particularly from China, exposes suppliers to geopolitical and trade policy risks, including tariffs, which could affect their business relationship with the company.
• **Creditors (Hercules Capital)**: The extension of the interest-only period on the loan agreement provides the company with more flexibility, and the company remains in compliance with all loan covenants, which is positive for creditors. The option for Hercules to invest in future equity rounds provides potential upside.

Next Steps

• Continue to engage with other MACs, third-party payors, clinical societies, and stakeholders to expand and maintain sufficient reimbursement for Dry Eye products, including TearCare.
• Focus commercial resources on supporting providers in geographies with established TearCare reimbursement to drive utilization.
• Target new and existing Eye Care Professionals (ECPs) in states with TearCare reimbursement to drive adoption.
• Expand additional third-party manufacturing locations outside of China, with new capacity expected in Q1 2026 for certain products, to mitigate tariff impacts.
• Continue strategic investments in product development, market access, sales and marketing, clinical studies, and education initiatives.
• Await court ruling on post-trial motions and judgment entry in the patent infringement lawsuit against Alcon.
• Monitor and respond to ex parte reexamination proceedings challenging the validity of asserted patents in the Alcon lawsuit.

Key Dates

Recommendation

The company's Q3 2025 results present a mixed picture. While significant cost-cutting measures, including a 20% workforce reduction, have led to a narrower net loss and improved operating loss, the underlying revenue decline, particularly in the Dry Eye segment, and increased cash burn from operations are concerning. The positive development of MAC pricing for TearCare offers a potential catalyst for future revenue growth, but its impact on demand is yet to be fully realized. The ongoing patent litigation, with the risk of reexamination proceedings overturning a favorable jury verdict, introduces substantial uncertainty. Given the company's continued losses, increased cash usage, and the volatility associated with its strategic transition and legal challenges, a 'hold' recommendation is appropriate. Investors should monitor the execution of the Dry Eye commercial strategy, the resolution of the patent dispute, and the effectiveness of cost controls before making further investment decisions.

Keywords

Ophthalmic Medical Device, Glaucoma, Dry Eye Disease, MIGS, TearCare, OMNI Surgical System, SION Surgical Instrument, SEC Filing, Financial Results, Reimbursement, Cost Reduction, Workforce Restructuring, Patent Litigation, Tariffs, Medical Technology